ciglitazone ciglitazone ciglitazone (inn) is a thiazolidinedione. developed by takeda pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class. ciglitazoneclinical dataatc codenoneidentifiers iupac name 5--1,3-thiazolidine-2,4-dione cas number74772-77-3 ypubchem cid2750iuphar/bps2711drugbankdb09201 ychemspider2648 nuniiu8qxs1wu8gkeggd03493 ychemblchembl7002 ncomptox dashboard (epa)dtxsid0040757 echa infocard100.220.474 chemical and physical dataformulac18h23no3smolar mass333.45 g·mol−13d model (jsmol)interactive image smiles o=c1nc(=o)sc1cc3ccc(occ2(c)ccccc2)cc3 inchi inchi=1s/c18h23no3s/c1-18(9-3-2-4-10-18)12-22-14-7-5-13(6-8-14)11-15-16(20)19-17(21)23-15/h5-8,15h,2-4,9-12h2,1h3,(h,19,20,21) nkey:yzfwtzacsrhjqd-uhfffaoysa-n n ny (what is this?) (verify) ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market. ciglitazone significantly decreases vegf production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome. ciglitazone is a potent and selective pparγ ligand. it binds to the pparγ ligand-binding domain with an ec50 of 3.0 μm. ciglitazone is active in vivo as an anti-hyperglycemic agent in the ob/ob murine model. inhibits huvec differentiation and angiogenesis and also stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells.